Samsung Biologics Achieves Record-Breaking Production Contract in 2024

A Historic Partnership Announcement

Samsung Biologics announced on January 14, 2025, that it signed its largest manufacturing deal ever—amounting to KRW 2.74 trillion (USD 2.14 billion) with a European pharmaceutical company. This contract accounts for 40% of the company’s total orders in 2024, which amounted to KRW 5.4 trillion, showing Samsung Biologics’ growing dominance in the global biopharmaceutical market.

This success came only three months after a record contract of KRW 1.7 trillion with an Asian pharmaceutical company. Samsung Biologics managed to secure three contracts in 2024 that were each valued at over KRW 1 trillion. The company’s cumulative global contract value now stands at USD 17.6 billion—a remarkable achievement.

Expansion to Meet Global Demand

Samsung Biologics is constructing its 5th plant to meet rising global demand for biologic drugs. This new facility is expected to produce 180,000 liters upon completion, combining the best practices from its first four plants. With the 5th plant operational, anticipated in April 2025, Samsung Biologics’ total production capacity will surpass an industry-leading 784,000 liters.

Serving 17 out of the world’s top 20 pharmaceutical companies, Samsung Biologics has become a preferred choice due to its exceptional manufacturing and operational efficiency. It boasts a 99% batch success rate, demonstrating consistent and superior output quality.

Global Recognition and Industry Leadership

As of late 2024, Samsung Biologics holds 340 regulatory approvals, including 41 from the U.S. FDA and 36 from the European Medicines Agency (EMA). Such regulatory success signifies the company’s ability to meet stringent global standards.

In addition to its operational achievements, Samsung Biologics participated in the 2025 JP Morgan Healthcare Conference in San Francisco (January 13–16), actively engaging with investors and expanding its business with potential international clients.

< Summary >
Samsung Biologics shattered records with a USD 2.14 billion manufacturing deal, representing 40% of its 2024 orders. The company continued to expand with the construction of its 5th plant to meet growing global biologic drug needs. Its high production efficiency and strong regulatory compliance have solidified its role as a leader in the biopharmaceutical industry, serving 17 of the top 20 global pharmaceutical companies.

< 핵심내용 요약 in Korean >
삼성바이오로직스는 2024년 총 수주액의 40%에 달하는 2조 747억 원 규모의 유럽 제약사와의 최대 계약을 달성했습니다. 더불어, 5공장 건설을 통해 글로벌 바이오의약품 수요에 발맞추어 생산 역량을 확장하고 있습니다. 99%의 배치 성공률과 340건의 글로벌 규제 승인으로, 전 세계 주요 제약사 20곳 중 17곳을 고객으로 확보하며 바이오 제약 산업에서 선도 기업으로 자리매김했습니다.

• Crafted by Billy Yang
  [관련글 at nextgeninsight.net/]
  Samsung Future in Biopharma Market
  Biologics Manufacturing Trends in 2025